News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos|
CNS Drug Development Resources
Advertisement

Elena Bravo

Advertisement

Articles by Elena Bravo

peer review logo.jpg

Point of View: Traceability and Transparency Should be Mandatory for All Human Biospecimens

ByPaul Hofman,Elena Bravo,Ann Cooreman,Alain J. van Gool,Michael H. A. Roehrl,Pascal Puchois
May 8th 2017

Transparency regarding the source of biospecimens would improve research quality, reproducibility, and translational use of acquired knowledge. Scientific robust publications, dissemination and communication are central to this-as are the regulatory reporting guidelines in play.

Advertisement

Latest Updated Articles

  • peer review logo.jpg
    Point of View: Traceability and Transparency Should be Mandatory for All Human Biospecimens

    Published: May 8th 2017 | Updated:



Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

ACT Brief: Rethinking Site Support in 2026, GSK’s New Severe Asthma Approval, and Priority Review Momentum in Multiple Myeloma

2

Unlocking Unstructured Health Data: Scaling eSource-Enabled Clinical Trials

3

FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data

4

Life Sciences Can’t Afford Fragmented Data and Disconnected Teams

5

ACT Brief: Neutral Tech Adoption at Sites, Scaling Unstructured Data for eSource, and Novo Nordisk’s CagriSema NDA

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us